As President of Theradex for over 20 years, Ms. Valnoski has led Theradex operations including full-service trial support throughout the US, EU and Asia. Ms. Valnoski oversees regulatory affairs in the US collaborating with Theradex’s lead clinical scientists and EU regulatory experts to provide clients global development strategies for oncology drug products ranging from standard cytotoxic approaches to targeted combinations. She works closely with the diverse team of experts within Theradex to support the ongoing efforts to increase knowledge and the technical tools necessary to ensure the successful execution of your clinical trial. She facilitates communication between the clinical trial management staff and systems developers to ensure that clients have both the knowledge and the tools available to manage all phases of oncology trials across regions. Ms. Valnoski draws upon extensive experience interacting with clients and the regulatory authorities to help clients navigate through the changing regulatory environment driven by the evolution of personalized treatment approaches.
Ms. Valnoski works with the company senior leadership to support collaborations that provide clients with the combined benefit of long-term clinical development and project execution experience.